诺诚健华、鞍石药业、福泰制药新药多点发力

医药经济报
16 Apr

诺诚健华1类新药申报上市今日,CDE官网显示,已受理诺诚健华新一代泛TRK抑制剂Zurletrectinib(ICP-723)用于治疗携带NTRK融合基因的晚期实体瘤成人和青少年(12周岁≤年龄<18周岁)患者的新药上市申请(NDA)。此外,卓乐替尼针对儿童患者(2周岁≤年龄<12周岁)的注册临床试验正在进行中。公司资料显示,NTRK融合基因可见于各种类型的成人及儿童肿瘤。在部分罕见肿瘤中,例如...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10